NewAmsterdam Pharma and Menarini Celebrate Positive CHMP Opinion for Obicetrapib Drugs

NewAmsterdam Pharma and Menarini Receive Positive CHMP Opinion

In a recent announcement, NewAmsterdam Pharma Company N.V. and Menarini Group celebrated a crucial milestone following a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The recommendation supports the marketing authorization of two innovative therapies: Ubeslo® (obicetrapib monotherapy) and Evlarco® (a fixed-dose combination of obicetrapib and ezetimibe). These drugs are designed to deal with primary hypercholesterolemia, including both heterozygous familial and mixed dyslipidemia cases.

Significance of the CHMP Opinion

Michael Davidson, CEO of NewAmsterdam Pharma, emphasized that this positive CHMP opinion marks a vital step for not only the company but also for patients in need of better solutions for managing their low-density lipoprotein cholesterol (LDL-C) levels. The need is particularly pressing for individuals who do not achieve their cholesterol targets with existing therapies. Obicetrapib’s formulation offers an oral medication that can be taken once daily, with or without food, addressing a significant unmet need in cardiovascular disease management.

Robust Clinical Data Supporting Approval

This recommendation is backed by comprehensive data from several Phase 3 trials, including the BROADWAY, BROOKLYN, and TANDEM studies. These trials have exhibited significant LDL-C reductions; patients using obicetrapib monotherapy displayed up to a 40% reduction in LDL-C compared to placebo. In combination with ezetimibe, the reduction was an impressive 50%. The tolerability profile of obicetrapib also aligns closely with placebo, indicating its potential safety.

Next Steps with the European Commission

The European Commission (EC) will now evaluate the CHMP's recommendation, and a final decision on the marketing authorization is anticipated in the second half of 2026. The EC has the authority to grant a centralized marketing authorization that would enable access across all member states of the European Union, along with Iceland, Liechtenstein, and Norway. Elcin Barker Ergun, CEO of Menarini, expressed optimism regarding the regulatory journey, highlighting the potential impact obicetrapib could have in helping patients achieve their LDL-C targets—an outcome many existing treatments have failed to deliver.

Commercial Rights and Future Prospects

Menarini holds exclusive commercialization rights for obicetrapib within Europe and carries the responsibility for all regulatory interactions and commercial activities in the area. NewAmsterdam anticipates receiving tiered double-digit royalties based on net sales in this region, with additional potential financial rewards amounting to €833 million conditional upon fulfilling specific clinical, regulatory, and commercial milestones.

Understanding Obicetrapib

Obicetrapib is an innovative oral low-dose CETP inhibitor aimed at overcoming the shortcomings of current LDL-lowering therapies. Detailed observations from several Phase 2 and Phase 3 trials indicate significant LDL-lowering effects, with a side effect profile akin to that of placebo. The ongoing PREVAIL cardiovascular outcomes trial demonstrates the commitment to assess obicetrapib's potential in reducing major cardiovascular events. Enrolled patients in this trial total over 9,500, which speaks volumes about the attention and funding directed towards this therapeutic pathway.

Addressing Global Cardiovascular Disease

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Despite the presence of lipid-lowering therapies, a large population—projected to reach over 184 million U.S. adults by 2050—is expected to be affected by CVD and hypertension. Obicetrapib represents a vital addition to the pharmaceutical arsenal against this prevalent health crisis.

Conclusion

As NewAmsterdam Pharma and Menarini await the European Commission's decision, the healthcare community and patients alike are hopeful. Should approval be granted, Ubeslo® and Evlarco® may not only improve treatment outcomes for a vast number of patients struggling with high cholesterol but also pave the way for continued innovation in cardiovascular care.